Compositions and methods for topical delivery of prostaglandins to subcutaneous fat

Abstract

Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject.

What is claimed is: 
     
         1 . A method for reducing body fat in a subject, the method comprising administering to the subject a composition comprising latanoprost, isopropyl myristate, and petroleum jelly. 
     
     
         2 . The method of  claim 1 , wherein the method locally reduces body fat in the subject. 
     
     
         3 . The method of  claim 1 , wherein the method reduces subcutaneous fat in the subject. 
     
     
         4 . The method of  claim 1 , wherein the composition consists essentially of latanoprost, isopropyl myristate, and petroleum jelly. 
     
     
         5 . The method of  claim 1 , wherein the latanoprost concentration is between about 0.001% and about 1% w/w, inclusive. 
     
     
         6 . The method of  claim 5 , wherein the latanoprost concentration is between about 0.01% and about 0.5% w/w, inclusive. 
     
     
         7 . The method of  claim 1 , wherein the isopropyl myristate concentration is between about 1% and about 20% w/w, inclusive. 
     
     
         8 . The method of  claim 7 , wherein the isopropyl myristate concentration is between about 1% and about 10% w/w, inclusive. 
     
     
         9 . The method of  claim 5 , wherein the isopropyl myristate concentration is between about 1% and about 20% w/w, inclusive. 
     
     
         10 . The method of  claim 9 , wherein the isopropyl myristate concentration is between about 1% and about 10% w/w, inclusive. 
     
     
         11 . The method of  claim 1 , wherein the petroleum jelly concentration is between about 70% and about 99% w/w, inclusive. 
     
     
         12 . The method of  claim 5 , wherein the petroleum jelly concentration is between about 70% and about 99% w/w, inclusive. 
     
     
         13 . The method of  claim 1 , further comprising a preservative. 
     
     
         14 . The method of  claim 13 , wherein the preservative is chlorobutanol. 
     
     
         15 . The method of  claim 1 , wherein the composition is sterile. 
     
     
         16 . The method of  claim 1 , wherein the latanoprost concentration is between about 0.001% and 1% w/w, inclusive; the isopropyl myristate concentration is between about 1% and about 10% w/w, inclusive; and the petroleum jelly concentration is between about 70% and about 99% w/w, inclusive. 
     
     
         17 . The method of  claim 1 , wherein the administering is about once a day. 
     
     
         18 . The method of  claim 1 , wherein the administering is to the face, chin, neck, arms, abdomen, chest, breast, buttocks, hips, thighs, legs, and/or knees. 
     
     
         19 . The method of  claim 1 , wherein the administering is to the eyelids. 
     
     
         20 . The method of  claim 1 , wherein the administering is to the submental region.